FEZF1-AS1

Across TCGA pan-cancer cohorts, FEZF1-AS1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of FEZF1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where FEZF1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FEZF1-AS1 is over-expressed in tumor.

COAD, STAD, and LUAD are the cancer types where FEZF1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FEZF1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+2.045	<.001	12	view →
STAD	Male	All	+2.096	<.001	9	view →
LUAD	Female	All	+1.655	<.001	9	view →
HNSC	Male	IV	+1.869	<.001	8	view →
LUSC	Female	II,III,IV	+2.035	<.001	7	view →
READ	All	All	+1.716	<.001	5	view →
LIHC	All	All	+0.613	<.001	5	view →
ESCA	All	All	+1.682	.009	4	view →
BLCA	All	All	+0.980	.005	4	view →
BRCA	Female	II,III,IV	+0.109	<.001	4	view →
PRAD	All	All	+0.217	<.001	2	view →
CHOL	All	All	+0.640	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

FEZF1-AS1–COAD

Open the COAD breakdown →